vendredi 11 décembre 2015

Onco Actu du 11 décembre 2015

1. Biologie

Researchers discover new aspect of gene regulation and a possible target for cancer drugs [The Rockefeller University]

Neutrophils prepare niche in the lung for breast cancer metastasis and colonization [NIHilist's Immunology]

3.1 Tabac

Tobacco companies challenge legality of UK plain packaging rules [The Guardian]

4.1 Dép., diag. & prono. - Prostate

Prostate cancer test is more reliable if done twice [The Telegraph]

5.2 Pharma

Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer [Pfizer]

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer [Aduro Biotech]

Cancer Drug Quest Drives Bayer to Accelerate Pipeline Investment [Bloomberg Business]

5.2.1 Pharma - Partenariats

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® (pembrolizumab) Combination Trial [Merck]

Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy [Bellicum Pharmaceuticals]

5.2.3 Pharma - économie

Puma falls on neratinib side effects []

5.3 Traitements - FDA, EMA,...

What We Mean When We Talk About Data [FDA Voice]

5.4 Traitements - Economie

NICE makes decisions on use of three innovative cancer drugs on NHS: ICR statement [The Institute of Cancer Research]

NICE publishes draft guidance on two prostate cancer treatments [NICE]

NICE publishes draft guidance on two prostate cancer treatments [Pharmafile]

5.7.1 SABCS-communiqués

Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium [Seattle Genetics]

myChoice HRD(TM) Test Identifies Breast Cancer Patients Likely to Respond to Platinum-Containing Therapies [Myriad]

Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer [Puma Biotechnology]

Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium [Puma Biotechnology]

NewLink Genetics Corporation Presents Preliminary Safety Data From Randomized Phase 2 Trial of Indoximod, an IDO Pathway Inhibitor, at San Antonio Breast Cancer Symposium [NewLink Genetics]

5.7.2 SABCS-divers

SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer [Colorado Cancer Blogs]

Clinical trial explores treatment for metastases while continuing overall breast cancer therapy [Colorado Cancer Blogs]

Mastectomy plus reconstruction has highest rate of complication, complication-related costs of guideline-concordant therapies for early breast cancer [MD Anderson Cancer Center]


Adding Carboplatin to Presurgery Chemotherapy Improved Disease-free Survival for Patients With Triple-negative Breast Cancer [AACR]

Analysis of Blood Samples Finds ESR1 Gene Mutations are Prevalent and Associated With Worse Overall Survival [AACR]

Mastectomy Plus Reconstruction has Higher Complication Rates and Costs Than Lumpectomy Plus Radiation [AACR]

Breast-conserving Therapy Yielded Better Outcomes Than Mastectomy for Early-stage Patients [AACR]

Resistance of ER-positive Breast Cancer to Tamoxifen Therapy May be Driven by APOBEC3B [AACR]

SABCS 2015: Denosumab Improves Outcomes for Patients Taking Aromatase Inhibitors [CANCER RESEARCH Catalyst]

6. Lutte contre les cancers

Grand Challenge two: wipe out cancers caused by the Epstein-Barr Virus [Cancer Research UK]

Creative Minds: Applying CRISPR Technology to Cancer Drug Resistance [NIH Director's Blog]

Precision Medicine Trials for Cancer: A New Era Begins [National Cancer Institute]

6.1 Observation

Delaying chemotherapy in breast cancer patients reduces overall survival, especially for those with triple-negative breast cancer [MD Anderson Cancer Center]

Study finds higher rates of advanced thyroid cancer in California [Reuters]

6.8 Communication

What the media got wrong about Jimmy Carter’s cancer “cure” [HealthNewsReview]